- Home
- IMCR vs CYD Comparison
IMCR vs CYD Comparison
Compare IMCR & CYD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- CYD
- Stock Information
- Founded
- IMCR 2008
- CYD 1951
- Country
- IMCR United Kingdom
- CYD Singapore
- Employees
- IMCR N/A
- CYD N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- CYD Industrial Machinery/Components
- Sector
- IMCR Health Care
- CYD Industrials
- Exchange
- IMCR Nasdaq
- CYD Nasdaq
- Market Cap
- IMCR 1.7B
- CYD 1.5B
- IPO Year
- IMCR 2021
- CYD 1994
- Fundamental
- Price
- IMCR $37.97
- CYD $35.53
- Analyst Decision
- IMCR Buy
- CYD
- Analyst Count
- IMCR 9
- CYD 0
- Target Price
- IMCR $67.00
- CYD N/A
- AVG Volume (30 Days)
- IMCR 270.5K
- CYD 175.8K
- Earning Date
- IMCR 11-06-2025
- CYD 08-08-2025
- Dividend Yield
- IMCR N/A
- CYD 1.50%
- EPS Growth
- IMCR N/A
- CYD 40.10
- EPS
- IMCR N/A
- CYD 1.66
- Revenue
- IMCR $379,590,000.00
- CYD $3,159,401,156.00
- Revenue This Year
- IMCR $30.11
- CYD $41.12
- Revenue Next Year
- IMCR $8.89
- CYD $6.93
- P/E Ratio
- IMCR N/A
- CYD $21.55
- Revenue Growth
- IMCR 28.11
- CYD 17.99
- 52 Week Low
- IMCR $23.15
- CYD $8.61
- 52 Week High
- IMCR $39.33
- CYD $42.60
- Technical
- Relative Strength Index (RSI)
- IMCR 68.17
- CYD 42.68
- Support Level
- IMCR $34.30
- CYD $33.64
- Resistance Level
- IMCR $38.17
- CYD $40.79
- Average True Range (ATR)
- IMCR 1.54
- CYD 1.84
- MACD
- IMCR 0.59
- CYD -0.36
- Stochastic Oscillator
- IMCR 96.54
- CYD 21.67
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About CYD China Yuchai International Limited
China Yuchai International Ltd is a Bermuda holding company that is a subsidiary of Singapore-based Hong Leong Asia. China Yuchai International operates through its majority-owned subsidiary Guangxi Yuchai Machinery Company, a China-based company that manufactures, assembles, and distributes diesel engines for various vehicles including trucks, buses, and cars, as well as construction and agricultural, marine, and power-generation equipment. It generates the majority of its sales from the Chinese market.